AstraZeneca Unveils Landmark Cancer Trial Results at ESMO 2025
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
Advertisement
Alamar Biosciences Launches Blood-Based pTau217 Assay for Alzheimer’s Research
FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a leader in precision proteomics, today announced the launch of...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Johnson & Johnson Launches CORE-VA Registry to Advance Arrhythmia Care
IRVINE, Calif., October 10, 2025 — Johnson & Johnson MedTech has announced the launch of the CORE-VA (Catheter-based Outcomes...
Celltrion Secures FDA Approval for EYDENZELT® in Multiple Retinal Diseases
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
Phibro Animal Health Licenses Novel Periodontal Therapy for Dogs
TEANECK, N.J., October 9, 2025 — Phibro Animal Health Corporation (NASDAQ: PAHC) announced a licensing agreement with Lighthouse Pharmaceuticals,...
Kedrion Biopharma Launches YIMMUGO® for PI in the U.S.
FORT LEE, N.J., October 9, 2025 — Kedrion Biopharma today announced the U.S. commercial launch of YIMMUGO® (Immune Globulin...
Stealth BioTherapeutics Expands Access with Mito Assist™ and AnovoRx Partnership
NEEDHAM, Mass., October 9, 2025 — Stealth BioTherapeutics Inc. has announced the launch of Mito Assist™, a comprehensive patient...
Hemostemix Seeks Ethics Approval for Stem Cell Dementia Trial
CALGARY, Alberta, Oct. 9, 2025 — Hemostemix has filed for Institutional Review Board (IRB) approval of its Phase 1...
Adcendo Secures FDA Fast Track for ADCE-D01 Targeting Soft Tissue Sarcoma
COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates...
Advertisement
